The world is still adjusting to the advent of the Presidential tweet, but pharmaceutical manufacturers shouldn’t overlook another milestone of the social media era: an FDA commissioner who is active on Twitter.
US FDA Commissioner Scott Gottlieb’s tenure at the agency began with a tried and true formula: an all hands address full of praise for the dedication and commitment of the career staff and outlining an agenda for his tenure.
Then he did something no commissioner has done before: he set up a new Twitter handle (@SGottliebFDA) and told his 37,000 followers on the site that he would tweet from...
Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.
The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.
